Resumes
Resumes
Jesper Gromada Phones & Addresses
-
98 Sandy Pond Rd, Concord, MA 01742 (978) 254-5221
-
197 Elsinore St, Concord, MA 01742
-
Scarsdale, NY
-
Cambridge, MA
-
Minneapolis, MN
-
62 Boulder Ridge Rd, Scarsdale, NY 10583
Publications
Us Patents
Methods Of Treating Cancers
View pageUS Patent:
20120076729, Mar 29, 2012
Filed:
Jun 2, 2010
Appl. No.:
13/375556
Inventors:
Dinh Le Mary Chau - Waltham MA, US
Jesper Gromada - Concord MA, US
Zhidan Wu - Boston MA, US
Jesper Gromada - Concord MA, US
Zhidan Wu - Boston MA, US
International Classification:
A61K 38/18
A61K 39/395
G01N 33/566
A61P 35/00
C12Q 1/68
G01N 33/573
A61K 49/00
A61K 31/713
A61K 39/395
G01N 33/566
A61P 35/00
C12Q 1/68
G01N 33/573
A61K 49/00
A61K 31/713
US Classification:
424 91, 4241581, 514 44 A, 514 91, 435 612, 435 721
Abstract:
The present application describes methods for treating and/or preventing cancer or a cancer symptom, e.g., AMPK-related cancers, in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an FGF, e.g., FGF21, or an FGF agonist, or a pharmaceutical composition comprising the same.
Hsd17B13 Variants And Uses Thereof
View pageUS Patent:
20220267743, Aug 25, 2022
Filed:
Mar 31, 2022
Appl. No.:
17/709965
Inventors:
- Tarrytown NY, US
Omri Gottesman - Tarrytown NY, US
Alexander Li - Tarrytown NY, US
Xiping Cheng - Tarrytown NY, US
Yurong Xin - Tarrytown NY, US
Jesper Gromada - Tarrytown NY, US
Frederick E. Dewey - Tarrytown NY, US
Aris Baras - Tarrytown NY, US
Alan Shuldiner - Tarrytown NY, US
Omri Gottesman - Tarrytown NY, US
Alexander Li - Tarrytown NY, US
Xiping Cheng - Tarrytown NY, US
Yurong Xin - Tarrytown NY, US
Jesper Gromada - Tarrytown NY, US
Frederick E. Dewey - Tarrytown NY, US
Aris Baras - Tarrytown NY, US
Alan Shuldiner - Tarrytown NY, US
International Classification:
C12N 9/04
C12N 15/113
C12Q 1/6883
C12Q 1/32
C12Q 1/6827
C12Q 1/6876
A61K 47/61
A61P 1/16
A61K 38/44
A61K 38/46
C12N 9/22
C12N 9/96
C12N 15/11
C12N 15/85
C12N 15/90
C12N 15/113
C12Q 1/6883
C12Q 1/32
C12Q 1/6827
C12Q 1/6876
A61K 47/61
A61P 1/16
A61K 38/44
A61K 38/46
C12N 9/22
C12N 9/96
C12N 15/11
C12N 15/85
C12N 15/90
Abstract:
Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B13 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.
Compositions And Methods For Enhancing Body Weight And Lean Muscle Mass Using Antagonists Against Leptin Receptor, Gdf8 And Activin A
View pageUS Patent:
20220220213, Jul 14, 2022
Filed:
Dec 17, 2019
Appl. No.:
17/415589
Inventors:
- Tarrytown NY, US
Jesper Gromada - Concord MA, US
Jesper Gromada - Concord MA, US
International Classification:
C07K 16/28
C07K 16/22
A61K 33/26
A61K 39/395
A61P 21/00
A61K 45/06
C07K 16/22
A61K 33/26
A61K 39/395
A61P 21/00
A61K 45/06
Abstract:
The present invention provides combinations including antagonists of leptin receptor, GDF8 and Activin A and methods of use thereof. Such compositions are effective for example for causing an increase in lean body mass, at least in part, at the expense of fat mass. Methods for treating malnutrition, cachexia and other conditions characterized by insufficient nutrition and weight loss are also provided.
Anti-Npr1 Antibodies And Uses Thereof
View pageUS Patent:
20220204634, Jun 30, 2022
Filed:
Mar 10, 2022
Appl. No.:
17/692084
Inventors:
- Tarrytown NY, US
Jia SU - Scarsdale NY, US
Jason MASTAITIS - Yorktown Heights NY, US
Jesper GROMADA - Scarsdale NY, US
Lori MORTON - Chappaqua NY, US
Jia SU - Scarsdale NY, US
Jason MASTAITIS - Yorktown Heights NY, US
Jesper GROMADA - Scarsdale NY, US
Lori MORTON - Chappaqua NY, US
International Classification:
C07K 16/28
Abstract:
The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.
Nucleic Acids Encoding Anchor Modified Antibodies And Uses Thereof
View pageUS Patent:
20220195014, Jun 23, 2022
Filed:
Dec 20, 2021
Appl. No.:
17/555616
Inventors:
- Tarrytown NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
John McWhirter - Greenville NC, US
Vera Voronina - North Bethesda MD, US
Jesper Gromada - Concord MA, US
Andrew J. Murphy - Croton-on-Hudson NY, US
John McWhirter - Greenville NC, US
Vera Voronina - North Bethesda MD, US
Jesper Gromada - Concord MA, US
International Classification:
C07K 16/00
C07K 14/58
A01K 67/027
C07K 14/58
A01K 67/027
Abstract:
Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.
Compositions And Methods For Treatment Of Disorders Associated With Repetitive Dna
View pageUS Patent:
20220186216, Jun 16, 2022
Filed:
Feb 25, 2022
Appl. No.:
17/681138
Inventors:
- Boston MA, US
Matthias Heidenreich - Boston MA, US
Norzehan Abdul-Manan - Boston MA, US
Lu Gan - Boston MA, US
Jianming Liu - Boston MA, US
Guoxiang Ruan - Boston MA, US
Jesper Gromada - Boston MA, US
John Patrick Leonard - Cambridge MA, US
Zachary Michael Detwiler - Cambridge MA, US
Peter Thomas Hallock - Cambridge MA, US
David Esopi - Boston MA, US
Giselle Dominguez Gutierrez - Boston MA, US
Matthias Heidenreich - Boston MA, US
Norzehan Abdul-Manan - Boston MA, US
Lu Gan - Boston MA, US
Jianming Liu - Boston MA, US
Guoxiang Ruan - Boston MA, US
Jesper Gromada - Boston MA, US
John Patrick Leonard - Cambridge MA, US
Zachary Michael Detwiler - Cambridge MA, US
Peter Thomas Hallock - Cambridge MA, US
David Esopi - Boston MA, US
Giselle Dominguez Gutierrez - Boston MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Boston MA
International Classification:
C12N 15/11
C12N 9/22
C12N 15/113
C12N 9/22
C12N 15/113
Abstract:
Compositions and methods for treating excising trinucleotide repeats, as well as for treating diseases and disorders associated with trinucleotide repeats are encompassed.
Hsd17B13 Variants And Uses Thereof
View pageUS Patent:
20230031669, Feb 2, 2023
Filed:
Sep 7, 2022
Appl. No.:
17/930180
Inventors:
- Tarrytown NY, US
Omri Gottesman - Rancho Sante Fe CA, US
Alexander Li - White Plains NY, US
Xiping Cheng - Northvale NJ, US
Yurong Xin - Stamford CT, US
Evangelos Pefanis - Somers NY, US
Suzanne Hartford - Putnam Valley NY, US
Jesper Gromada - Concord MA, US
Frederick E. Dewey - Winchester MA, US
Aris Baras - Bedford Corners NY, US
Alan Shuldiner - Baltimore MD, US
Omri Gottesman - Rancho Sante Fe CA, US
Alexander Li - White Plains NY, US
Xiping Cheng - Northvale NJ, US
Yurong Xin - Stamford CT, US
Evangelos Pefanis - Somers NY, US
Suzanne Hartford - Putnam Valley NY, US
Jesper Gromada - Concord MA, US
Frederick E. Dewey - Winchester MA, US
Aris Baras - Bedford Corners NY, US
Alan Shuldiner - Baltimore MD, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C12N 9/04
C12N 15/113
C12Q 1/6883
A61K 31/713
G01N 33/50
C12Q 1/32
C12Q 1/6827
C12Q 1/6876
A61K 47/61
A61P 1/16
A61K 38/44
A61K 38/46
C12N 9/22
C12N 9/96
C12N 15/11
C12N 15/85
C12N 15/90
C12N 15/113
C12Q 1/6883
A61K 31/713
G01N 33/50
C12Q 1/32
C12Q 1/6827
C12Q 1/6876
A61K 47/61
A61P 1/16
A61K 38/44
A61K 38/46
C12N 9/22
C12N 9/96
C12N 15/11
C12N 15/85
C12N 15/90
Abstract:
Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.
Aplnr Modulators And Uses Thereof
View pageUS Patent:
20210403551, Dec 30, 2021
Filed:
Feb 4, 2021
Appl. No.:
17/167990
Inventors:
- Tarrytown NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Jesper Gromada - Scarsdale NY, US
Yonaton Ray - Bergenfield NJ, US
Jee H. Kim - Ardsley NY, US
Ivan B. Lobov - New York NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Jesper Gromada - Scarsdale NY, US
Yonaton Ray - Bergenfield NJ, US
Jee H. Kim - Ardsley NY, US
Ivan B. Lobov - New York NY, US
International Classification:
C07K 16/28
C07K 14/705
C07K 14/72
A61K 39/395
A61K 38/22
C07K 14/47
C07K 19/00
C07K 16/46
C07K 14/705
C07K 14/72
A61K 39/395
A61K 38/22
C07K 14/47
C07K 19/00
C07K 16/46
Abstract:
The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.